Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed December 2, 2015. Bunn, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 95, 341, 10.1093/jnci/95.5.341 Belani, 2005, Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326), Cancer, 104, 2766, 10.1002/cncr.21495 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Zhou, 2015, BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer, J Clin Oncol, 33, 2197, 10.1200/JCO.2014.59.4424 Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 Paz-Ares, 2013, PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, J Clin Oncol, 31, 2895, 10.1200/JCO.2012.47.1102 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Barlesi, 2013, Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089), J Clin Oncol, 31, 3004, 10.1200/JCO.2012.42.3749 Barlesi, 2014, Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial, Ann Oncol, 25, 1044, 10.1093/annonc/mdu098 Patel, 2013, J Clin Oncol, 31, 4349, 10.1200/JCO.2012.47.9626 Patel, 2009, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer, J Clin Oncol, 27, 3284, 10.1200/JCO.2008.20.8181 Gridelli, 2003, J Clin Oncol, 21, 3025, 10.1200/JCO.2003.06.099 Smit, 2003, Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975, J Clin Oncol, 21, 3909, 10.1200/JCO.2003.03.195 Georgoulias, 2005, Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 23, 2937, 10.1200/JCO.2005.04.016 Pujol, 2005, Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin, Ann Oncol, 16, 602, 10.1093/annonc/mdi126 Treat, 2010, A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer, Ann Oncol, 21, 540, 10.1093/annonc/mdp352 Kosmidis, 2002, Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 20, 3578, 10.1200/JCO.2002.12.112 Stathopoulos, 2004, Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial, Ann Oncol, 15, 1048, 10.1093/annonc/mdh260 Stathopoulos, 2007, Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial, Lung Cancer, 57, 66, 10.1016/j.lungcan.2007.02.003 Jiang, 2013, Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naive advanced non-small-cell lung cancer in the era of third-generation agents, J Cancer Res Clin Oncol, 139, 25, 10.1007/s00432-012-1294-z Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Pietanza, 2013, Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial, J Clin Oncol, 31, 2004, 10.1200/JCO.2012.45.8117 Basch, 2005, Patient online self-reporting of toxicity symptoms during chemotherapy, J Clin Oncol, 23, 3552, 10.1200/JCO.2005.04.275 Basch, 2007, Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities, J Am Med Inform Assoc, 14, 264, 10.1197/jamia.M2177 Basch, 2007, Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy, J Clin Oncol, 25, 5374, 10.1200/JCO.2007.11.2243 Basch, 2016, Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial, J Clin Oncol, 34, 557, 10.1200/JCO.2015.63.0830 Basch, 2015, Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer clinical treatment trial, ClinTrials Hayes, 2016, Comparison of CT volumetric measurements with RESIST response in patients with lung cancer, Eur J Radiol, 85, 524, 10.1016/j.ejrad.2015.12.019 Rizvi, 2008, Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer, J Clin Oncol, 26, 639, 10.1200/JCO.2007.10.8605 Paik, 2011, A phase 2 study of weekly albumin-bound paclitaxel (Abraxane) given as a two-hour infusion, Cancer Chemother Pharmacol, 68, 1331, 10.1007/s00280-011-1621-0 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Besse, 2015, Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study, Clin Cancer Res, 21, 1896, 10.1158/1078-0432.CCR-14-2082 Akerley, 2003, Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B, Cancer, 97, 2480, 10.1002/cncr.11375 Belani, 2008, Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer, J Clin Oncol, 26, 468, 10.1200/JCO.2007.13.1912 Zinner, 2015, J Thorac Oncol, 10, 134, 10.1097/JTO.0000000000000366 Gridelli, 2014, Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study, J Thorac Oncol, 9, 991, 10.1097/JTO.0000000000000207 D'Angelo, 2011, A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed, J Thorac Oncol, 6, 624, 10.1097/JTO.0b013e318207f788 Bastos, 2010, Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer, J Thorac Oncol, 5, 533, 10.1097/JTO.0b013e3181ce3e00 Nagata, 2010, Severe interstitial pneumonitis associated with the administration of taxanes, J Infect Chemother, 16, 340, 10.1007/s10156-010-0058-4 Dhakal, 2011, Pemetrexed induced pneumonitis, Clin Pract, 1, e106, 10.4081/cp.2011.e106 Breuer, 2012, Pemetrexed-induced lung toxicity: a case report, Clin Oncol (R Coll Radiol), 24, 76, 10.1016/j.clon.2011.08.009 Goldberg, 1995, Pneumonitis related to treatment with paclitaxel, J Clin Oncol, 13, 534, 10.1200/JCO.1995.13.2.534 Kim, 2010, A case of pemetrexed-induced acute lung injury in non-small cell lung cancer, J Thorac Oncol, 5, 401, 10.1097/JTO.0b013e3181c5b198